apixaban and carbamazepine: what the product label says

The product label for apixaban names carbamazepine in its drug-interaction information. The complete selected section is reproduced below so that qualifications stay with the finding.

Which products this evidence covers

ELIQUIS — TABLET, FILM COATED — ORAL

Labeled active ingredients: APIXABAN. Routes: ORAL. Dosage forms: TABLET, FILM COATED.

Supporting label passage

Section: 7.2 Combined P-gp and Strong CYP3A4 Inducers

Avoid concomitant use of ELIQUIS with combined P-gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John’s wort) because such drugs will decrease exposure to apixaban [see Clinical Pharmacology (12.3) ] .

Read the full product label on DailyMed. Label version 23, dated 2024-11-25.

Limits of this evidence

This passage applies to the labeled product and circumstances it describes. It must not be generalized to other routes or formulations. It does not independently validate CDI’s severity category, establish safety for an individual, or replace the full label. The stored interaction description and classification have not been changed by this article.

How this brief was prepared

Automatic checks matched drug identities, retrieved and preserved the label, and checked the full quoted section with AI assistance on 2026-11-05. The public explanation uses a fixed template; model-written medical advice is not published. Independent clinical review has not been recorded.

Discuss your exact medicines with your pharmacist

Ask your pharmacist or prescriber whether the cited products, routes and circumstances apply to your medicines before changing treatment.

Check your medication list with CDI.